Everything you need to know
about biosimilars in one place

Expert Panel Discusses Biosimilars Impact

A panel of health industry leaders, hosted by the Alliance for Health Reform, gathered together representatives from Hospira, Amgen, the FDA and other industry experts to discuss the future of biosimilars in the U.S.   Alliance executive vice president, Ed Howard, moderated the event, where expert panelists discussed the U.S. and global markets for reference … Continue reading Expert Panel Discusses Biosimilars Impact

Read more

Prescribers, Pharmacists and Patients: Negotiating the Issues Around Biosimilars

  With Zarxio’s entry into the U.S. market still pending, pharmacists need to be aware of biosimilars in order to better assist their patients.   While the U.S.’s first approved biosimilar, Zarxio is yet to be available to prescribers and patients amid ongoing legal battles, the fact is that biosimilars will soon be a reality … Continue reading Prescribers, Pharmacists and Patients: Negotiating the Issues Around Biosimilars

Read more

What Do Doctors Think?

In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologic medicines labelling.   It found: In 2013, the ASBM also surveyed 470 European physicians, from the United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines.   … Continue reading What Do Doctors Think?

Read more